Catyalyst Pharmaceutical Partners (CPRX) Updates on Firdapse Phase 3; Plans Rolling NDA Submissions in Early FY15
Tweet Send to a Friend
Catyalyst Pharmaceutical Partners (Nasdaq: CPRX) has provided an update on the progress of its Phase 3 study of Firdapse (amifampridine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
